The article presents a modern view on anti-osteoporotic medication therapy in patients with various forms of Braitsev-Lichtenstein disease. Against the background of fundamental studies of the bone tissue’s structural condition in this pathology improved and tested medication correction of its disorders depending on changes in bone metabolism, shape, clinical and orthopedic manifestations of the disease, the patient’s age.
The article presents the rationale, general principles and features of anti-osteoporotic therapy; indications and contraindications to it; dose calculations and regimens for the use of certain medications, including from the group of bisphosphonates in various forms of Braitsev-Lichtenstein disease.
The presented medication therapy has been successfully tested in 16 patients with Braitsev-Lichtenstein disease. The effectiveness of the treatment is confirmed by the reduction or elimination of pain, stopping the progression of pathological diseases on average in the bones of the lower extremities, improving the structural condition of bone tissue and its metabolism.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
Braitsev VR. Fibrous osteodystrophy. M.: Medgiz. 1947. 123 р.
Volkov MV, Abalmasova EA, Dedova VD, Ter-Ehyazarov HN. Pediatric Traumatology and Orthopedics. M.: Medicine. 1983. 460 р.
Volkov MV, Samoilova LY. Fibrous osteodysplasia. M.: Medicine. 1973. 167 р.
Dolnytskyi OV. Congenital malformations. Basics of diagnosis and treatment. K .: Business polygraph; 2009. 516-523.
Zatsepyn ST. Bone pathology of adults. M .: Medicine. 2001. 512 р.
Horacio Plotkin, Frank Rauch, Leonid Zeitlin, Craig Munns, Rose-Travers, Francis H. Glorieux Effect of Pamidronate Treatment in Children with Polyostotic Fibrous Dysplasia of Bone J. Clin. Endocr. &Metabol. 2003;88:4569-75.
Zacharin M, O’Sullivan M. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune-Albright syndrome. J Pediatr. 2000;137:403-9.
Chapurlat R.D., Delmas P.D., Liens D., Meunier P.J. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res. 1997;12:1746-52.
Pfeilschifter J, Ziegler R. Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome. Med Klin. 1998;93:352-9.
Lala R, Matarazzo P, Bertelloni S, Buzi F, Rigon F, de Sanctis C Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. Acta Paediatr. 2000;89:188-93.
Serum Cross Laps: pediatric reference intervals from birth to 19 years of age. Crofton P. M., Evans N., Taylor M. R. H., Holland C. V. Clin. Chemistry. 2002;48(4):671-3.
Procollagen Type I amino-terminal propeptide: pediatric reference data and relations hip with procollagen type I carboxy l-terminal propeptide. Crofton P. M., Evans N., Taylor M. R. H., Holland, C. V. Clin. Chemistry. 2004;50(11):2173-6.